This article is more than 5 years old. Information may no longer be current.
PCI, CABG may both be options in left main disease
Click Here to Manage Email Alerts
Similar rates of MACCE were reported for PCI and CABG in a cohort of individuals with unprotected left main disease, concluded recent findings.
The researchers noted that the recommended treatment for significant de novo left main stenosis is CABG, but that a class IIa indication has been given for PCI in select patients with unprotected disease. The current analysis was an investigation of 5-year outcomes for these two approaches among 1,800 patients with left main or three-vessel disease in the SYNTAX trial. Patients in the PCI group received Taxus Express paclitaxel-eluting stents (Boston Scientific).
There were 705 patients in the unprotected left main cohort.
At 5 years, the MACCE rate was 36.9% in the PCI group and 31% for CABG (HR=1.23; 0.95-1.59). The mortality rate at this point was 12.8% for PCI and 14.6% for CABG (HR=0.88; 0.58-1.32).
PCI yielded a stroke incidence rate of 1.5% compared with 4.3% for CABG, which the researchers noted was a significant difference (HR=0.33; 0.12-0.92). Repeat revascularization was significantly higher in the PCI arm compared with CABG (26.7% vs. 15.5%; HR=1.82; 1.28-2.57).
Among individuals with low or intermediate SYNTAX scores, MACCE rates did not differ between the two groups. However, MACCE was increased in those with high scores (≥33) in the PCI group.
“At 5 years, no difference in overall MACCE was found between treatment groups,” the researchers concluded. “These results suggest that both treatments are valid options for [left main] patients. The extent of disease should [be] accounted for when choosing between surgery and PCI, as patients with high SYNTAX scores seem to benefit more from surgery compared to the lower [tertiles].”
Disclosure: The researchers report financial disclosures with Abbott and Boston Scientific.
Click Here to Manage Email Alerts